Virtus Biotech Clinical Trials ETF
17 hedge funds and large institutions have $2.67M invested in Virtus Biotech Clinical Trials ETF in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 0 closing their positions.
34% more capital invested
Capital invested by funds: $1.99M → $2.67M (+$680K)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
6% more funds holding
Funds holding: 16 → 17 (+1)
5.79% more ownership
Funds ownership: 16.52% → 22.31% (+5.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$629K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$22.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$11.9K |
| 4 |
ODG
O'Dell Group
Cincinnati,
Ohio
|
+$2.82K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.76K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$111K |
| 2 |
LPL Financial
San Diego,
California
|
-$39.1K |
| 3 |
Morgan Stanley
New York
|
-$20.2K |
BBC Hedge Fund Activity: Q2 2023 in Review
17 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q2 2023, worth a combined $2.67M — up 34% from $1.99M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BBC positions and 0 closed out — a net gain of 2 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $629K. The largest seller was Royal Bank of Canada, cutting an estimated $111K.
- 17 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q2 2023, up from 16 in Q1 2023.
- Funds reported $2.67M of Virtus Biotech Clinical Trials ETF stock for Q2 2023, up 34% quarter-over-quarter.
- 2 funds opened new Virtus Biotech Clinical Trials ETF positions in Q2 2023 and 0 closed out, a net change of +2 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q2 2023 was Susquehanna International Group, an estimated $629K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q2 2023 was Royal Bank of Canada, an estimated $111K sold.
Based on aggregated 13F filings for Q2 2023.